Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 796.26

-0.6%

Jan 9 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: Patrick Slevin who wrote ()	6/1/1996 10:38:00 PM
From:	of 3559

I've followed REGN since 01/01/95. Roy Vagelos was CEO of Merck and retired in 1994. He became Chairman of Board of REGN in January 95. The stock was at 3 but went immediately to 6.(Luckly I bought then). As you noted it has since gone to 18+. Roy Vagelos was named to the Fortune Mag.'s National Business Hall of Fame in 1995. He certainly would not destroy a great reputation by going into some fly-by-night company. I think it has great potential, however the Annual Report came today and it's only potential, the earnings are a long way off. On Prodigy in Company News dated 5/28/96 Josephthal Lyon & Ross' analyst Franklin Berger raised his rating from hold to buy and set a 12-month target price of 34 on the stock. I'm not familiar with the analyst or the broker. Just thought you may be interested.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext